Central nervous system hemangioma is a rare, benign cluster of extra blood vessels in the brain or spinal cord. It can cause headaches, seizures, or weakness, and doctors may see it on MRI. Many people with central nervous system hemangioma have stable features for years, but some lesions can bleed and need quick care. Treatment often includes careful monitoring, seizure control, or surgery or focused radiation if there is pressure or bleeding. The outlook is usually good, and most people live normal lifespans with the right care.
Overview
Central nervous system hemangiomaSymptoms
Central nervous system hemangioma may cause headaches, seizures, or sudden neurologic changes. Early symptoms of central nervous system hemangioma include vision or balance problems, weakness or numbness, and speech trouble. Some people have no signs; lesions are sometimes found incidentally.
Outlook and prognosis
Most central nervous system hemangiomas are slow-growing and remain stable for years. Outlook depends on size and location—lesions near critical brain or spinal pathways are more likely to cause symptoms, but timely imaging and tailored treatment often protect function. Regular follow-up helps catch changes early.
Causes and risk factors
Central nervous system hemangioma usually forms from abnormal blood‑vessel development before birth. Some cases run in families due to changes in blood‑vessel genes; others are new. Risk may rise with family history, prior brain radiation, and certain rare syndromes.
Genetic influences
Genetics play a limited, context-specific role in central nervous system hemangioma. Most lesions are sporadic, but some relate to inherited conditions like von Hippel–Lindau or hereditary hemorrhagic telangiectasia. Somatic mutations (e.g., MAPK/PIK3CA pathways) can drive growth and guide targeted therapies.
Diagnosis
Diagnosis of Central nervous system hemangioma relies on MRI showing typical features; CT can help if bleeding is suspected. Genetic tests may be used with multiple lesions or family history, supporting genetic diagnosis of Central nervous system hemangioma.
Treatment and drugs
Treatment for central nervous system hemangioma focuses on protecting brain or spinal cord function and easing symptoms. Options may include careful MRI monitoring, targeted medications (such as steroids or beta‑blockers), focused radiation, or surgery when growth or bleeding causes pressure. Care is individualized by neurology and neurosurgery teams.
Symptoms
Central nervous system hemangioma can press on nearby brain or spinal cord tissue or bleed, leading to problems that depend on where it sits. Early symptoms of central nervous system hemangioma may be subtle, like new headaches, brief numbness, or short spells of vision changes. Symptoms vary from person to person and can change over time.
Pressure or irritation from a central nervous system hemangioma can trigger new or worsening headaches, sometimes on one side or deep behind the eyes. Headaches may come and go or build gradually; a sudden, severe headache can signal bleeding and needs urgent care.
Brain irritation from a central nervous system hemangioma can cause brief staring spells, jerking, or loss of awareness. Some notice a warning feeling, odd smells, or flashing lights just before an event.
Symptoms depend on the area involved and may affect the face, arm, or leg on one side. Tasks like gripping a mug or buttoning a shirt can feel clumsier than usual.
Blurred or double vision, blind spots, or trouble focusing can develop if the parts of the brain that handle sight are involved. You might notice small changes at first when reading or navigating steps.
How people usually first notice Central nervous system hemangioma?
Many people first notice a central nervous system hemangioma when new, unexplained headaches, seizures, or a sudden neurologic change—like weakness, numbness, vision problems, or trouble with balance—prompts imaging. Sometimes it’s found by accident on an MRI or CT scan done for another reason, or after a minor head injury draws attention to it. In infants and young children, doctors may first suspect it if there’s a related skin hemangioma on the head or neck alongside developmental delays or abnormal neurologic exams, leading to imaging that confirms the first signs of central nervous system hemangioma.
Types of Central nervous system hemangioma
Central nervous system hemangioma can look different from person to person, largely based on where it forms in the brain or spinal cord and how it behaves over time. Clinicians often describe them in these categories: location-based types, growth pattern, and whether they affect the surrounding tissue or cause bleeding. Understanding the main types of CNS hemangioma and how symptoms differ can help you and your care team plan monitoring or treatment. Not everyone will experience every type.
Cavernous malformation
These are clusters of abnormal, thin-walled blood vessels that can leak or bleed. Symptoms often include seizures, headaches, or brief neurological changes like numbness or vision shifts. Bleeding risk and symptoms may change over time.
Capillary hemangioma
These are made of many small capillaries and often show up in infants or children but can occur in adults. They may cause symptoms only if they press on nearby brain or spinal cord tissue. Vision issues, headaches, or weakness can appear depending on location.
Venous malformation
These are enlarged, slow-flow veins that usually grow with the person and rarely bleed. Many people with this type have few or no symptoms, and it is often found on scans done for another reason. Headache or mild neurological symptoms can occur if nearby tissue is compressed.
Arteriovenous malformation
These are fast-flow tangles of arteries and veins without normal capillaries between them. They can cause headaches, seizures, or sudden neurological symptoms if bleeding occurs. For many, the first sign is a sudden bleed in the brain.
Spinal involvement
When a hemangioma affects the spinal cord or its coverings, back pain or a band-like chest or abdominal pain can be early symptoms. Numbness, tingling, or weakness in the legs can develop if the cord is compressed or if bleeding occurs. Bladder or bowel changes may appear with more severe pressure.
Brainstem lesions
Lesions in the brainstem can cause double vision, facial weakness, swallowing trouble, or balance problems. Even small bleeds here can produce noticeable symptoms because the area is compact and critical. Care teams often monitor these closely.
Cerebellar lesions
In the cerebellum, symptoms often center on coordination, balance, and fine movements. People may notice clumsiness, unsteady walking, or trouble with precise hand tasks. Headaches and nausea can occur if pressure builds.
Supratentorial lesions
Lesions in the upper parts of the brain may cause seizures, headaches, or changes in speech, strength, or sensation. Early symptoms of central nervous system hemangioma here often reflect the function of the affected lobe. Memory or concentration changes can show up with frontal or temporal involvement.
What genetics can tell you about symptoms
Some central nervous system hemangiomas link to inherited changes in genes that guide blood vessel growth, like KRIT1/CCM1, CCM2, or PDCD10/CCM3. These variants can lead to headaches, seizures, or neurological changes, and multiple lesions that appear earlier and recur.
Causes and risk factors
Most central nervous system hemangiomas form from abnormal clusters of tiny blood vessels that develop before birth, and the trigger is often unknown. Some risks are written in our DNA, passed down through families. These vascular growths can be part of conditions like cerebral cavernous malformations or von Hippel–Lindau syndrome, and they can also occur without any family history. Prior radiation to the brain or spine can raise the chance of developing one, and lifestyle factors have little impact on forming them. Family history, prior radiation, and certain inherited syndromes are among the main risk factors for central nervous system hemangioma.
Environmental and biological risk factors
Understanding what raises the chance of a central nervous system hemangioma can help you and your care team focus on monitoring. Risk factors are different from early symptoms of central nervous system hemangioma; they describe conditions that make it more likely to form. Doctors often group risks into internal (biological) and external (environmental). Many of these factors are present from birth and may only come to light when imaging is done for another reason.
Treatment radiation to the head or spine can lead to new cavernous hemangiomas years later. Risk appears higher after childhood or teen exposure and with higher treatment doses.
A common vein variation in the brain, sometimes called a developmental venous anomaly, can sit next to a hemangioma. When this vein pattern is present, a cavernous hemangioma is more likely to form in that area.
Differences in how brain or spinal cord blood vessels formed before birth can set the stage for a hemangioma. These vessel patterns are present from birth, even if the hemangioma is only noticed later.
Genetic risk factors
Genetics can influence who develops central nervous system hemangioma, especially forms that involve clusters of fragile blood vessels in the brain or spinal cord. Carrying a genetic change doesn’t guarantee the condition will appear. Genetic testing may be considered when there are multiple lesions, a family history, or early symptoms of central nervous system hemangioma such as seizures or recurrent headaches.
KRIT1 (CCM1): Changes in the KRIT1 gene can cause familial clusters of cavernous lesions in the brain or spine, sometimes called cavernous hemangiomas. People may have one or many lesions, and symptoms vary from none to headaches or seizures. Relatives can be checked if a KRIT1 change is confirmed.
CCM2 gene: Variants in CCM2 can also lead to cerebral cavernous malformations. Some people notice problems only after an MRI finds the lesions, while others have symptoms earlier. Families may show different patterns even with the same change.
PDCD10 (CCM3): PDCD10 changes often present at a younger age and can be linked to more numerous lesions. This gene has been associated with a higher chance of symptoms and brain bleeds in childhood or early adulthood. Care teams may recommend closer follow-up when PDCD10 is involved.
Autosomal-dominant pattern: When a CCM gene change is inherited, each child has a 50% chance of inheriting it. Some carriers never develop symptoms, while others may have significant issues. A genetics professional can explain testing options for relatives.
De novo or mosaicism: A person can be the first in the family with a CCM gene change due to a new (de novo) variant. Mosaic changes—present in only some cells—can create clusters of lesions but may be missed on standard blood testing. Specialized testing or tissue analysis may be needed to confirm mosaicism.
Founder KRIT1 variant: A historic KRIT1 change is relatively common in some families with roots in Mexico and the Southwestern United States. This ‘founder’ variant can lead to multiple brain or spinal lesions across several generations. Genetic counseling can help families discuss screening in at-risk relatives.
PHACE association: Large, segmental infantile hemangiomas of the face or scalp can occur with brain artery differences and, rarely, intracranial hemangiomas (the PHACE spectrum). No single gene explains PHACE, and most cases appear sporadic rather than inherited. When present, brain imaging is tailored to the child’s pattern of findings.
Lifestyle risk factors
Central nervous system hemangioma is not caused by lifestyle choices, but daily habits can influence symptom flares, seizure risk, and chances of bleeding. Focusing on how lifestyle affects Central nervous system hemangioma can help you reduce triggers and protect brain and spinal function. The points below highlight practical, behavior-based factors linked to headaches, seizures, or hemorrhage risk—key lifestyle risk factors for Central nervous system hemangioma.
Regular high-salt eating can raise blood pressure, which may increase the chance of hemangioma bleeding or pressure-related headaches. Choosing lower-sodium meals helps keep blood pressure steadier and may lessen neurologic symptom flares.
Heavy or binge drinking can spike blood pressure and impair clotting, which may heighten hemorrhage risk from a CNS hemangioma. Moderate to no alcohol use can reduce headache frequency and bleeding risk.
Large or late-day caffeine intake can raise blood pressure and trigger headaches in people with CNS vascular lesions. Limiting caffeine may reduce head pain and stabilize blood pressure swings.
Intense straining or powerlifting can cause abrupt pressure surges in the head and spine, potentially provoking headaches or neurological symptoms around a hemangioma. Favoring controlled, lower-strain strength work may reduce these flares.
Risk prevention
Most central nervous system hemangiomas form because of how blood vessels develop, often from birth, so there’s no reliable way to prevent the condition itself. The goal is to lower the chance of complications like bleeding or seizures and to catch changes early. Prevention is about lowering risk, not eliminating it completely. If you have a family history, or notice early symptoms of central nervous system hemangioma such as new seizures, sudden weakness, or severe headaches, ask about timely evaluation and follow-up.
Periodic check-ins with a neurologist or neurosurgeon can spot changes early. MRI scans may be advised if symptoms change or if a familial pattern is present.
If central nervous system hemangioma runs in your family, genetic counseling can guide testing and screening. Relatives at risk may benefit from baseline and follow-up imaging.
Discuss blood thinners and antiplatelet drugs with your doctor before starting them. For some people with central nervous system hemangioma, these medicines may raise bleeding risk.
Keeping blood pressure in a healthy range may reduce strain on fragile vessels. Home checks and regular visits help you stay on track.
Transmission
Central nervous system hemangioma isn’t contagious—you can’t catch it or pass it on through contact. Most central nervous system hemangiomas occur sporadically and are not inherited. When they do run in families, they typically follow an autosomal dominant pattern: if a parent carries the gene change, each child has a 50% chance of inheriting it. Sometimes a new (de novo) change appears for the first time in a child, so there may be no prior family history. If there’s a family pattern or multiple brain or spinal findings, a genetics professional can explain how central nervous system hemangioma is inherited and whether testing is appropriate.
When to test your genes
Consider genetic testing if central nervous system hemangiomas are multiple, unusually large, recur, or appear with other vascular findings, or if there’s a family history of similar lesions. Testing is also reasonable when diagnosis is unclear or results could change surgery, imaging frequency, or targeted therapy. Discuss timing with a genetics-informed specialist.
Diagnosis
You might notice sudden headaches, seizures, or new weakness that disrupt daily routines, which often prompts a medical visit. It’s natural to worry when symptoms don’t have a clear explanation. Doctors confirm the diagnosis of Central nervous system hemangioma primarily with MRI, and then tailor testing based on symptoms and location. Some cases are found after a minor head scan for another reason, and careful follow-up helps sort out what’s urgent and what can be watched.
Your doctor checks strength, sensation, balance, vision, and reflexes. These findings help pinpoint which part of the brain or spine may be involved. They also guide which tests to order first.
MRI of the brain or spine shows the size, number, and location of lesions. It’s the main test to evaluate a suspected Central nervous system hemangioma. Contrast dye can help outline the borders and nearby swelling.
Susceptibility‑weighted imaging is an MRI setting that is very sensitive to tiny blood products. It can reveal small or multiple lesions that standard MRI might miss. This helps confirm the pattern seen with Central nervous system hemangioma.
A head CT is fast and can detect recent bleeding, especially in emergency settings. It’s helpful when symptoms start suddenly with severe headache or neurologic changes. MRI usually follows to provide more detail.
Stages of Central nervous system hemangioma
Central nervous system hemangioma does not have defined progression stages. These vascular lesions often stay stable for long periods, and symptoms tend to flare if there’s bleeding or pressure on nearby brain or spinal tissue rather than a steady, predictable decline; early symptoms of central nervous system hemangioma can include headaches, seizures, numbness, or vision changes, depending on location. Different tests may be suggested to help confirm what’s happening, most often an MRI of the brain or spine (sometimes with contrast) and a neurological exam. Ongoing care usually involves watchful follow-up with repeat imaging, and referral to a neurosurgeon or neurovascular specialist if symptoms worsen or the imaging changes.
Outlook and prognosis
Looking ahead can feel daunting, but most central nervous system (CNS) hemangiomas grow slowly and many stay stable for long stretches. The outlook depends on where the hemangioma sits—brain versus spinal cord—and whether it presses on nearby tissue. When symptoms do appear, they often come from pressure effects, like headaches, seizures, balance trouble, or limb weakness, rather than from the lesion itself being “aggressive.” In medical terms, the long-term outlook is often shaped by both genetics and lifestyle.
Many people ask, “What does this mean for my future?”, and the answer is usually that careful monitoring and timely treatment lead to good outcomes. Early care can make a real difference, whether that means watchful MRI follow‑up or a planned procedure to prevent worsening symptoms. For spinal cord hemangiomas, surgery can relieve pressure and improve function, especially if done before nerve changes become permanent. In the brain, treatment decisions balance the risk of growth or bleeding against the risks of surgery or radiation.
Serious complications like major bleeding are uncommon, but they can occur, which is why doctors watch for early symptoms of central nervous system hemangioma such as new seizures, sudden severe headache, or fast‑changing weakness. Mortality directly due to a CNS hemangioma is rare, and most people have a normal life span, particularly when the lesion is found early and managed in a center experienced with these vascular tumors. Everyone’s journey looks a little different. Talk with your doctor about what your personal outlook might look like.
Long-term effects
Central nervous system hemangioma can have a very different long-term course depending on where it sits in the brain or spinal cord, whether it has bled, and if it was removed or observed. Long-term effects vary widely and depend on location and past bleeding. Some remain stable for years, while others cause symptoms that come and go. Over time, the main concerns are seizures, neurological changes, and bleeding that can leave lasting effects.
Recurrent seizures can develop or persist, especially after a prior bleed or irritation of nearby brain tissue. For some, early symptoms of central nervous system hemangioma include a first seizure. Seizure patterns may stay stable or flare with new bleeding.
Ongoing or intermittent headaches are common, sometimes worsening after minor bleeds. They can range from dull pressure to severe pain. Sensitivity to light or nausea may accompany episodes.
Some hemangiomas can leak or bleed, which may cause sudden symptoms or leave lingering deficits. The chance of another bleed often relates to the lesion’s location and prior bleeding. New bleeding can reset recovery and lead to stepwise changes over time.
Weakness, numbness, or speech or vision changes can persist if brain tissue was injured. These changes may plateau or slowly improve over months. Sometimes they reappear or worsen after another bleed.
How is it to live with Central nervous system hemangioma?
Living with a central nervous system hemangioma often means navigating uncertainty: symptoms can ebb and flow, from headaches or seizures to balance, vision, or sensation changes, depending on where the lesion sits. Daily life may involve regular MRI check-ins, medication to manage symptoms like seizures or pain, and planning around fatigue or flare days, with extra care to avoid injury if there’s a bleeding risk. Many find that routines, clear safety plans, and open communication at work and home help keep life steady, while family and friends may take on supportive roles—driving to appointments, spotting early warning signs, or simply helping pace the day. Emotional ripples are common for everyone involved, but counseling, support groups, and a strong partnership with a neurology or neurosurgery team can restore confidence and control.
Treatment and drugs
Treatment for central nervous system hemangioma focuses on protecting brain or spinal cord function, easing symptoms, and reducing the risk of bleeding or pressure on nearby tissue. Small, quiet lesions found by accident are often watched with regular MRI scans, while symptomatic or enlarging hemangiomas may be treated with surgery to remove the lesion and relieve pressure. When surgery carries higher risk due to location, doctors may consider targeted radiation (stereotactic radiosurgery) to shrink or stabilize the hemangioma, and medicines that ease symptoms are called supportive therapies—for example, anti-seizure drugs for seizures, pain medicines for headaches, or steroids for short-term swelling. Treatment plans often combine several approaches, and follow-up imaging helps check healing and guide next steps. Ask your doctor about the best starting point for you, especially if you notice new or worsening neurological symptoms like seizures, weakness, or vision changes.
Non-drug treatment
Central nervous system hemangioma can affect movement, speech, vision, or balance depending on where it sits in the brain or spine. Beyond prescriptions, supportive therapies can help reduce risks like bleeding and protect day-to-day function. Treatment plans are tailored to the lesion’s size, location, and any symptoms, and they often combine procedures with rehabilitation. Some options focus on monitoring and safety, while others aim to shrink or remove the lesion when needed.
Regular MRI scans track size and any changes in nearby brain or spinal cord tissue. This is common when the central nervous system hemangioma is small and not causing symptoms. It also helps catch early symptoms of central nervous system hemangioma so treatment can begin promptly.
Highly focused radiation targets the lesion while sparing healthy tissue. It is noninvasive and may lower bleeding risk over months to years. This can be useful for deep or hard-to-reach areas.
Lower doses of radiation are given over several sessions. This approach may be used when a central nervous system hemangioma is near critical structures. It can be chosen if surgery would carry higher risk.
A tiny catheter blocks feeding blood vessels to reduce blood flow to the lesion. This can make surgery safer or sometimes serve as a stand-alone step to lower bleeding risk. It is performed by specialists in blood vessel procedures.
Your genes may have an impact on how drugs work for you
Medicines for central nervous system hemangioma can work differently from person to person because gene variants affect how drugs are absorbed, broken down, and reach brain or spinal cord tissue. Pharmacogenetic testing may guide safer dosing or alternative options to limit side effects.
Pharmacological treatments
Medicines for central nervous system hemangioma aim to control symptoms and complications. They do not remove the lesion, but they can ease early symptoms of central nervous system hemangioma such as headaches, seizures, or swelling. Not everyone responds to the same medication in the same way. Choices depend on age, lesion type, location, and whether surgery or radiation is planned or has already been done.
Levetiracetam, lamotrigine, or lacosamide can lower the chance of seizures triggered by the lesion. Doses are adjusted to control events with the fewest side effects. Your team may switch or combine drugs if seizures continue.
Dexamethasone can shrink inflammation around the hemangioma and relieve pressure symptoms like headache or weakness. It is usually used short term because longer use carries risks such as high blood sugar and infection.
In infants with intracranial or spinal infantile hemangioma, propranolol may shrink the tumor and ease symptoms under close specialist supervision. Heart rate, blood pressure, and blood sugar are monitored during treatment.
For complex or refractory vascular tumors or malformations, sirolimus may slow growth and reduce pain or swelling when other options are limited. It is off‑label and requires regular blood tests and infection precautions.
Genetic influences
Central nervous system hemangioma can sometimes be influenced by gene changes, but many cases happen by chance with no clear inherited cause. Family history is one of the strongest clues to a genetic influence. In families with a hereditary form, a single altered gene can raise the likelihood of developing multiple vascular lesions in the brain or spine, often earlier in life. If a parent carries such a change, each child has about a 1 in 2 (50%) chance of inheriting it, and the impact can vary widely—from no symptoms at all to issues like headaches or seizures depending on where the lesion sits. Occasionally, these growths appear as part of a broader syndrome that may also involve the eyes, kidneys, or skin, which can help point to a specific genetic cause. If you have more than one lesion or several relatives with similar findings, consider asking about genetic counseling and whether genetic testing for central nervous system hemangioma could clarify risks for you and your family.
Is Central nervous system hemangioma genetic?
Genetics play a limited, context-specific role in central nervous system hemangioma. Most lesions are sporadic, but some relate to inherited conditions like von Hippel–Lindau or hereditary hemorrhagic telangiectasia. Somatic mutations (e.g., MAPK/PIK3CA pathways) can drive growth and guide targeted therapies.
Pharmacogenetics—how genetics influence drug effects
Genetic findings can sometimes shape how treatment is planned, from timing of surgery to whether medicines are added. In a subset of people, vascular tumors in the brain or spinal cord occur with inherited conditions such as von Hippel–Lindau (VHL) syndrome; in that setting, targeted drugs like belzutifan may be considered alongside standard care. For others, if an infantile‑type lesion is treated medically (for example with a beta‑blocker such as propranolol or with steroids), differences in genes that handle drug breakdown can influence dose needs and the chance of side effects, though routine testing isn’t always necessary. Alongside your medical history and current medicines, genetic testing can sometimes identify how your body processes a medicine so your team can choose a safer starting dose or an alternative. If seizures are part of the picture and carbamazepine is being considered, screening for certain HLA types is recommended in some ancestries to reduce the risk of rare, severe skin reactions. If you’re weighing medications for central nervous system hemangioma—including targeted therapies or beta‑blockers—ask in a specialist clinic whether tumor or inherited genetic results could refine options or open clinical trial pathways.
Interactions with other conditions
People with a central nervous system hemangioma often navigate how it interacts with other health issues, especially conditions that affect blood vessels, blood clotting, or brain function. Doctors call it a “comorbidity” when two conditions occur together. Seizure disorders, migraines, and high blood pressure can overlap, and sometimes each can make the other feel more intense or harder to control. Because early symptoms of central nervous system hemangioma can look like common problems—such as headaches, seizures, or balance changes—it’s easy for signs to blend with issues like migraine, anxiety, or past concussions. Blood thinners, anti-clotting medicines, and bleeding disorders may raise the chance of bleeding in a vascular lesion, while pregnancy-related hormonal changes can occasionally make a lesion swell. Some people have an inherited syndrome, like von Hippel–Lindau (VHL), where hemangioma-like lesions can occur in the brain and spinal cord along with growths in other organs, so coordinated care across specialties is important.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Families and communities once noticed patterns of newborns with red-blue swellings on the head or spine that sometimes caused seizures, weakness, or trouble feeding. Midwives and early doctors recorded cases where a baby seemed well but later developed headaches, vision changes, or limb stiffness, only to find a blood-filled growth pressing on the brain or spinal cord during examination or after death.
Throughout history, people have described sudden declines after minor head injuries or fevers, which we now understand could have triggered bleeding inside a fragile cluster of vessels. Early surgeons occasionally encountered these lesions while treating skull fractures or doing exploratory procedures, noting how even a small cut could cause brisk bleeding they struggled to control. Without imaging, central nervous system hemangioma was often confused with “tumors” in general, infections, or stroke.
First described in the medical literature as vascular “angiomas,” these lesions were grouped with many other blood vessel malformations. As medical science evolved, careful autopsy work in the 1800s and early 1900s separated fast-flow problems like arteriovenous malformations from slower, sponge-like clusters more consistent with hemangiomas. Even then, the brain and spinal forms were thought to be exceedingly rare because they were hard to recognize during life.
The turning point came with modern imaging. Pneumoencephalography and angiography offered the first glimpses, but computed tomography (CT) in the 1970s and, especially, magnetic resonance imaging (MRI) in the 1980s and 1990s allowed doctors to see small vascular growths in living patients. Once considered rare, now recognized as more common than earlier records suggested, central nervous system hemangioma began to be diagnosed before severe complications occurred. MRI also helped distinguish these lesions from other vascular conditions and from cancers, which changed treatment decisions and reduced unnecessary surgery.
Over time, descriptions became more precise. Pediatric and adult forms were separated, and links to skin hemangiomas in infants were noted. Surgeons and radiation specialists compared outcomes and refined approaches to lower the risk of bleeding, swelling, or nerve damage. Pathologists clarified features under the microscope, showing how these vessel-rich growths differ from other brain and spinal lesions.
Advances in genetics added another layer. While many central nervous system hemangiomas appear sporadically, research into genes that guide vessel growth helped explain why some lesions enlarge rapidly in infancy and then shrink, while others remain stable or cause problems later. These insights encouraged watchful waiting in some cases and timely treatment in others.
Each stage in history has added to the picture we have today. What began as scattered case notes has become a clearer understanding supported by imaging, pathology, and careful follow-up. Knowing the condition’s history helps explain why diagnosis and care are far more accurate and safer now than they were just a few decades ago.